Antioxidants for Alzheimer disease: A randomized clinical trial with cerebrospinal fluid biomarker measures

Archives of Neurology

Volumn 69, Issue 7, 2012, Pages 836-841

  Galasko, Douglas R ^a   Peskind, Elaine ^d   Clark, Christopher M ^e   Quinn, Joseph F ^f   Ringman, John M ^b   Jicha, Gregory A ^g   Cotman, Carl ^c   Cottrell, Barbara ^a   Montine, Thomas J ^d   Thomas, Ronald G ^a   Aisen, Paul ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e AVID RADIOPHARMACEUTICALS   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN[1-42]; ASCORBIC ACID; ISOPROSTANE DERIVATIVE; PLACEBO; TAU PROTEIN; TAU PROTEIN 181; THIOCTIC ACID; UBIQUINONE; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE COOPERATIVE STUDY ACTIVITIES OF DAILY LIVING SCALE; ARTICLE; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FEMALE; FUNCTIONAL STATUS; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SUPPLEMENTATION; TREATMENT DURATION;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALPHA-TOCOPHEROL; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIOXIDANTS; ASCORBIC ACID; BIOLOGICAL MARKERS; CHOLINESTERASE INHIBITORS; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; F2-ISOPROSTANES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEMANTINE; MENTAL STATUS SCHEDULE; MIDDLE AGED; PEPTIDE FRAGMENTS; RETROSPECTIVE STUDIES; TAU PROTEINS; THIOCTIC ACID; UBIQUINONE;

EID: 84863798026     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2012.85     Document Type: Article

References (38)

1. Lovell MA, Markesbery WR. Oxidative damage in mild cognitive impairment and early Alzheimer's disease. J Neurosci Res. 2007;85(14):3036-3040. (Pubitemid 350057358)
2. Montine TJ, Neely MD, Quinn JF, et al. Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic Biol Med. 2002;33(5):620-626. (Pubitemid 35245834)
3. Morris MC. The role of nutrition in Alzheimer's disease: epidemiological evidence. Eur J Neurol. 2009;16(suppl 1):1-7.
4. Yaffe K, Clemons TE, McBee WL, Lindblad AS; Age-Related Eye Disease Study Research Group. Impact of antioxidants, zinc, and copper on cognition in the elderly: a randomized, controlled trial. Neurology. 2004;63(9):1705-1707. (Pubitemid 39507595)
5. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):23-33.
6. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease: the Alzheimer's Disease Cooperative Study. N Engl J Med. 1997;336(17):1216-1222. (Pubitemid 27183651)
7. Petersen RC, Thomas RG, Grundman M, et al Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352(23):2379-2388. (Pubitemid 40958434)
8. Floyd RA, Hensley K. Oxidative stress in brain aging: implications for therapeutics of neurodegenerative diseases. Neurobiol Aging. 2002;23(5):795-807. (Pubitemid 35217704)
9. Smith AR, Shenvi SV, Widlansky M, Suh JH, Hagen TM. Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Curr Med Chem. 2004;11(9):1135-1146. (Pubitemid 38585058)
10. Sung S, Yao Y, Uryu K, et al. Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB J. 2004;18(2):323-325.
11. Harrison FE, Allard J, Bixler R, et al. Antioxidants and cognitive training interact to affect oxidative stress and memory in APP/PSEN1 mice. Nutr Neurosci. 2009;12(5):203-218.
12. Garcia-Alloza M, Dodwell SA, Meyer-Luehmann M, Hyman BT, Bacskai BJ. Plaque-derived oxidative stress mediates distorted neurite trajectories in the Alzheimer mouse model. J Neuropathol Exp Neurol. 2006;65(11):1082-1089. (Pubitemid 44684666)
13. Cotman CW, Head E. The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches. J Alzheimers Dis. 2008;15(4):685-707.
14. Quinn JF, Bussiere JR, Hammond RS, et al. Chronic dietary alpha-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice. Neurobiol Aging. 2007;28(2):213-225. (Pubitemid 44894634)
15. Siedlak SL, Casadesus G, Webber KM, et al. Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer's disease. Free Radic Res. 2009;43(2):156-164.
16. Hager K, Kenklies M, McAfoose J, Engel J, Münch G. Alpha-lipoic acid as a new treatment option for Alzheimer's disease: a 48months follow-up analysis. J Neural Transm Suppl. 2007;72(72):189-193.
17. Beal MF.Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. J Bioenerg Biomembr. 2004;36(4):381-386. (Pubitemid 39619845)
18. Yang X, Yang Y, Li G, Wang J, Yang ES. Coenzyme Q10 attenuates beta-amyloid pathology in the aged transgenic mice with Alzheimer presenilin 1mutation. J Mol Neurosci. 2008;34(2):165-171.
19. Wadsworth TL, Bishop JA, Pappu AS, Woltjer RL, Quinn JF. Evaluation of coenzyme Q as an antioxidant strategy for Alzheimer's disease. J Alzheimers Dis. 2008;14(2):225-234. (Pubitemid 352040040)
20. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-944. (Pubitemid 14076461)
21. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
22. Galasko D, Kershaw PR, Schneider L, Zhu Y, Tariot PN. Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease. J Am Geriatr Soc. 2004;52(7):1070-1076. (Pubitemid 38869064)
23. Thal LJ, Kantarci K, Reiman EM, et al. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20(1):6-15. (Pubitemid 44356888)
24. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131-144.
25. Galasko D, Montine TJ. Biomarkers of oxidative damage and inflammation in Alzheimer's disease. Biomark Med. 2010;4(1):27-36.
26. Montine TJ, Beal MF, Cudkowicz ME, et al. Increased CSF F2-isoprostane concentration in probable AD. Neurology. 1999;52(3):562-565. (Pubitemid 29075604)
27. Ringman JM, Younkin SG, Pratico D, et al. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology. 2008;71(2):85-92.
28. Olsson A, Vanderstichele H, Andreasen N, et al. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem. 2005;51(2):336-345. (Pubitemid 40175803)
29. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988;75(4):800-802. doi:10.2307/2336325.
30. Blennow K, Zetterberg H, Minthon L, et al. Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neurosci Lett. 2007;419(1):18-22. (Pubitemid 46694097)
31. Matthews RT, Yang L, Browne S, Baik M, Beal MF. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci U S A. 1998;95(15):8892-8897.
32. Shults CW, Oakes D, Kieburtz K, et al Parkinson Study Group. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002;59(10):1541-1550.
33. Kaufmann P, Thompson JL, Levy G, et al QALS Study Group. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol. 2009; 66(2):235-244.
34. Thal LJ, Grundman M, Berg J, et al. Idebenone treatment fails to slow cognitive decline in Alzheimer's disease. Neurology. 2003;61(11):1498-1502. (Pubitemid 37505568)
35. Wray DW, Nishiyama SK, Monnet A, et al. Antioxidants and aging: NMR-based evidence of improved skeletal muscle perfusion and energetics. Am J Physiol Heart Circ Physiol. 2009;297(5):H1870-H1875.
36. Miller ER III, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142(1):37-46.
37. Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006;12(7):856-861. (Pubitemid 44050079)
38. Hesse C, Rosengren L, Andreasen N, et al. Transient increase in total tau but not phosphotau in human cerebrospinal fluid after acute stroke. Neurosci Lett. 2001;297(3):187-190. (Pubitemid 32011305)